The Ongoing Debate Over Anticoagulation in Systemic Sclerosis

Clinicians have long debated the clinical role of anticoagulation in systemic sclerosis patients who develop precapillary pulmonary hypertension. Historically, physicians prescribed oral anticoagulants for idiopathic pulmonary arterial hypertension based on observational registries suggesting survival advantages. However, extrapolating these historical findings to systemic sclerosis remains clinically problematic. Systemic sclerosis represents an autoimmune disorder with microvascular vasculopathy, progressive fibrosis, and bleeding diatheses. Consequently, applying anticoagulation regimens indiscriminately exposes vulnerable scleroderma patients to serious clinical hazards. Furthermore, historical data in scleroderma-associated pulmonary hypertension showed conflicting results, leaving medical teams uncertain regarding risk-benefit ratios. In addition, patients with scleroderma face substantial risks of internal hemorrhage from gastrointestinal vascular ectasias. Therefore, the lack of dedicated prospective evidence has perpetuated divergent therapeutic practices. Cardiologists and rheumatologists must balance potential antithrombotic advantages against substantial bleeding complications. Because precapillary pulmonary hypertension carries high morbidity, clinicians required definitive real-world evidence to guide daily practice.

Study Design and Methodology of the EUSTAR Registry Analysis

To resolve this longstanding controversy, investigators analyzed data from the European Scleroderma Trials and Research group database. Specifically, researchers evaluated both overall mortality and pulmonary hypertension worsening among scleroderma patients with hemodynamic confirmation. All participants demonstrated precapillary pulmonary hypertension verified objectively by standardized right heart catheterization. In addition, the investigative team accounted for scleroderma-specific risk factors to eliminate confounding variables. The cohort included 614 patients, with 143 receiving oral anticoagulants at baseline catheterization. Notably, patients receiving anticoagulation presented with significantly more compromised baseline hemodynamic profiles. Therefore, to minimize confounding by indication, the researchers applied multivariable Cox proportional hazards regression models. Furthermore, the investigators conducted propensity score matching to establish balanced comparison groups between treated and untreated individuals. Consequently, this rigorous methodological framework enabled a robust evaluation of whether oral anticoagulants confer genuine clinical protection.

Key Findings on Survival Outcomes and Disease Progression

The study results revealed that oral anticoagulation did not confer any demonstrable survival benefit in systemic sclerosis. Specifically, multivariable Cox models demonstrated a survival hazard ratio of 0.983, with confidence intervals from 0.724 to 1.334. Similarly, anticoagulation therapy failed to prevent disease worsening, showing a hazard ratio of 1.070 with confidence intervals from 0.811 to 1.412. Moreover, these neutral outcomes remained consistent across all secondary analyses, including the propensity score-matched cohort. Thus, accounting for baseline hemodynamic disparities confirmed that anticoagulation provided no tangible protection against disease progression. Although earlier historical studies hinted at microthrombosis prevention, this contemporary analysis shows no clinical translation into measurable outcomes. Consequently, clinicians should not expect routine anticoagulant prescriptions to alter the trajectory of pulmonary vascular remodeling. Therefore, these findings strongly argue against empiric anticoagulation solely for precapillary vascular involvement.

Subgroup Considerations and Interstitial Lung Disease Phenotypes

Precapillary pulmonary hypertension in systemic sclerosis frequently occurs either as isolated pulmonary arterial hypertension or secondary to interstitial lung disease. Because pulmonary parenchymal involvement profoundly affects prognosis, the EUSTAR investigators conducted targeted subgroup evaluations. Specifically, they analyzed a subcohort comprising 230 patients who exhibited precapillary pulmonary hypertension without underlying interstitial lung disease. Even within this isolated vascular phenotype, oral anticoagulants conferred no statistically significant advantage regarding survival or clinical stability. Furthermore, patients suffering from concurrent interstitial lung disease face amplified risks of severe respiratory complications and alveolar hemorrhage. Therefore, eliminating confounding from fibrotic lung disease did not unmask hidden therapeutic benefits. Consequently, whether scleroderma patients present with pure vascular remodeling or combined cardiopulmonary pathology, oral anticoagulants fail to demonstrate effectiveness. As a result, multidisciplinary medical teams must avoid empiric anticoagulation across both phenotypes unless distinct secondary indications demand antithrombotic therapy.

Clinical Implications and Bleeding Risks in Scleroderma Care

These robust real-world findings carry direct clinical consequences for practicing physicians, particularly regarding safety profiles in scleroderma care. Systemic sclerosis patients frequently harbor occult gastric antral vascular ectasias, widespread mucosal telangiectasias, and impaired vascular integrity. Consequently, systemic anticoagulation poses an alarming hazard of life-threatening gastrointestinal hemorrhage and recurrent severe anemia. Because the EUSTAR analysis demonstrated zero clinical efficacy regarding mortality or disease worsening, the risk-benefit balance heavily tilts against anticoagulant therapy. Furthermore, international pulmonary hypertension guidelines advise against routine anticoagulation in scleroderma-associated pulmonary arterial hypertension. Clinicians must instead prioritize modern, targeted pulmonary arterial hypertension therapies, including prostacyclin pathway agonists, endothelin receptor antagonists, and phosphodiesterase inhibitors. Moreover, physicians should reserve anticoagulants strictly for compelling independent indications, such as documented atrial fibrillation or acute venous thromboembolism. Therefore, avoiding unnecessary anticoagulation shields vulnerable patients from preventable hemorrhagic harm while directing clinical attention toward proven vasodilator therapies.

Future Directions and Individualized Patient Stratification

Although this extensive EUSTAR cohort provides compelling evidence against routine anticoagulation, research questions persist. Specifically, further prospective studies must determine whether selected patient subsets derive therapeutic value from antithrombotics. In addition, future investigations should evaluate whether autoantibody profiles, hypercoagulable biomarkers, or microvascular phenotypes modify treatment responses. Additionally, prospective registries must assess direct oral anticoagulants separately from traditional vitamin K antagonists with higher bleeding propensities. In the interim, clinicians should adopt an individualized approach to clinical decision-making. Therefore, physicians must investigate bleeding diatheses, screen for occult vascular lesions, and optimize supportive therapy. Furthermore, close collaboration between cardiologists, pulmonologists, and rheumatologists remains essential to achieve cardiopulmonary risk reduction. Ultimately, current evidence dictates a conservative anticoagulation strategy, ensuring that decisions prioritize patient safety, proven vasodilators, and meticulous clinical monitoring.

Frequently Asked Questions

Do oral anticoagulants improve survival in systemic sclerosis patients with precapillary pulmonary hypertension?

Recent evidence from the large EUSTAR cohort study clearly demonstrates that oral anticoagulants do not improve overall survival in systemic sclerosis patients with precapillary pulmonary hypertension. Specifically, statistical analysis showed a neutral hazard ratio of 0.983, with no significant difference between treated and untreated groups. Furthermore, anticoagulants did not delay disease progression. Therefore, current scientific evidence does not support prescribing anticoagulants to prolong life in this patient group.

Why are systemic sclerosis patients at higher bleeding risk when taking oral anticoagulants?

Systemic sclerosis causes widespread microvascular damage, leading to fragile vascular lesions such as gastric antral vascular ectasias, widely known as watermelon stomach, and intestinal telangiectasias. Consequently, systemic anticoagulation markedly amplifies the risk of occult gastrointestinal bleeding, severe anemia, and sudden hemorrhage. Because anticoagulants provide no proven survival benefit in precapillary pulmonary hypertension, the heightened risk of bleeding complications substantially outweighs any theoretical antithrombotic advantage in this fragile patient population.

When should clinicians consider prescribing anticoagulants to scleroderma patients?

Clinicians should strictly restrict oral anticoagulants in scleroderma patients to standard clinical indications rather than using them for pulmonary hypertension management. Accepted indications include confirmed deep vein thrombosis, acute pulmonary embolism, mechanical heart valves, and atrial fibrillation with high thromboembolic risk. In these specific clinical scenarios, physicians must carefully screen patients for gastrointestinal telangiectasias and closely monitor hemoglobin levels to minimize hemorrhagic complications while delivering necessary antithrombotic therapy.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. It is not intended to replace consultation with a qualified healthcare professional. While we strive to provide accurate and up-to-date information, medical knowledge is constantly evolving. Healthcare professionals should make decisions based on their independent clinical judgment, taking into account each patient's unique clinical profile and circumstances. Patients should always consult their physician before making any healthcare decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Farina N et al. Effectiveness of oral anticoagulants in precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study. Rheumatology (Oxford). 2026 Sep 18. doi: undefined. PMID: 42758145.


2. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618-3731.


3. Bruni C, Farina N, Bellando-Randone S, et al. Risk stratification and therapeutic management in systemic sclerosis-associated pulmonary arterial hypertension. Current Opinion in Rheumatology. 2024;36(6):415-423.